)
Visual
earnings real time
Edwards Lifesciences (EW) investor relations material
Edwards Lifesciences Investor Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor Day 2025 summary4 Dec, 2025
Strategic vision and innovation
Focus on large, complex unmet patient needs with a strategy to lead and define new therapeutic categories, including TAVR, tricuspid, mitral, pulmonic, and aortic regurgitation therapies, and a patient-centered approach to structural heart disease.
Expanded reach through global presence in 100+ countries, 16,000 employees, and a resilient supply chain, with a strong culture and impact on the healthcare ecosystem.
Heavy R&D investment: over $1B annually, $1.6B external, with above 20% R&D return, 10,000+ patents, 1,000+ publications, and $40B+ in population-wide health gain from TAVR.
Diversified growth drivers now include TAVR, mitral, tricuspid, surgical, and emerging opportunities in structural heart failure and aortic regurgitation.
Commitment to continuous innovation and long-term value creation for patients, physicians, health systems, and shareholders.
Financial guidance and growth outlook
2025 guidance: 8%-10% total sales growth, TAVR growth 5%-7%, TMTT sales growth 50%-60% to $500M+, and EPS of $2.40-$2.50.
2026 guidance: 8%-10% sales growth, $6.4B-$6.8B sales, adjusted EPS $2.80-$2.95, operating margin expansion of ~100bps, and TAVR $4.6-$4.9B (6%-8% growth), TMTT $740-$780M (35%-45% growth), Surgical $1.05-$1.13B (mid-single digit growth).
Long-term: Targeting ~10% average annual sales growth, double-digit EPS growth, TMTT to reach $2B by 2030, and mid- to high-single-digit TAVR growth.
Capital deployment focused on R&D, strategic acquisitions, manufacturing, and share repurchases, maintaining >20% ROIC and a strong, flexible balance sheet.
Continued investment in R&D and adjacent therapies, with a focus on clinician and patient education and improving R&D ratio as a percent of sales.
Product and clinical pipeline highlights
TAVR: SAPIEN platform remains the global benchmark, with new indications, SAPIEN 3 Ultra RESILIA adoption, SAPIEN X4, and pivotal PROGRESS trial data expected at TCT 2026.
TMTT: Launches of EVOQUE, PASCAL, and SAPIEN M3 to expand patient pool; FDA approval of SAPIEN M3 expected early 2026; robust evidence from TRISCEND II and CLASP II trials.
Surgical: INSPIRIS, KONECT, MITRIS with RESILIA tissue technology showing strong adoption; U.S. launch of TRIFORMIS, the first surgical tricuspid valve, expected H2 2026.
Heart failure: Cordella system and new IHFM business targeting 1.2M high-risk patients, with PRO2 trial to support guideline updates and V-LAP in development.
AR: Acquisitions of J-Valve and JenaValve to address aortic regurgitation, with clinical trials underway and JenaValve acquisition pending.
Asymptomatic trial: disease vs device trial implications?
SAPIEN valve dock: key US market learnings?
Strategy to overcome skepticism for new therapies?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Edwards Lifesciences earnings date
Q4 202513 Feb, 2026
Next Edwards Lifesciences earnings date
Q4 202513 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Edwards Lifesciences Corporation is an innovative medical-device company, providing products in structural heart disease, and critical care and surgical monitoring that can improve healthcare worldwide. Our comprehensive portfolio includes devices for chronic total occlusions (CTO) repair and treatment of mitral valve disease (MVD). We also design and manufacture mechanical circulatory support devices, including the bioresorbable percutaneous ventricular assist device (BiVAD(TM)) used in advanced heart failure. Edwards Lifesciences Corporation is based in Irvine, California.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage